NCT05158244View on ClinicalTrials.gov

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PF-07081532

Study Drug, once daily for 42 days

DRUG

Placebo

Placebo, once daily for 42 days

Trial Locations (1)

33143

Qps-Mra, Llc, South Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05158244 - Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter